Core Insights - Harbour BioMed has entered a multi-year global strategic collaboration with Bristol Myers Squibb to develop next-generation multi-specific antibodies [1][2] - The agreement includes potential payments totaling $90 million and up to $1.035 billion in development and commercial milestones, along with tiered royalties [2] Company Overview - Harbour BioMed is a global biopharmaceutical company focused on discovering and developing novel antibody therapeutics in immunology and oncology [4] - The company aims to build a robust portfolio through internal R&D, collaborations, and selective acquisitions [4] Technology and Innovation - The proprietary Harbour Mice technology platform generates fully human monoclonal antibodies in various formats, enhancing the therapeutic potential of biologics [5] - The HCAb-based immune cell engagers (HBICE) technology allows for tumor-killing effects that traditional therapies cannot achieve, making the antibody discovery engine unique and efficient [5] Strategic Collaboration - The collaboration with Bristol Myers Squibb is expected to leverage Harbour BioMed's technology and development capabilities, particularly in conducting early clinical trials in China [3]
Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with Bristol Myers Squibb to Discover and Develop Next-Generation Multi-Specific Antibodies